近年,新型减肥药的兴起让诺和诺德一度成为欧洲市值最高的公司,美国礼来也跃升为全球最大的制药集团。然而,这股热潮似乎正在迅速退却。 根据英国《金融时报》报道,由于新药临床试验结果令人失望,以及连续两个季度的销售数据低于预期,两家公司的股价已从历史高点回落。诺和诺德失去了欧洲市值最高公司的宝座,而减肥药相关股票已进入熊市区域。 尽管分析师预测,未来十年,减肥药市场规模将超过1000亿美元,但一些投资者...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.